Investors
and Media

Investor Overview

Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

  • Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] was approved by the FDA on May 3, 2018. Learn more.
  • Bevyxxa® (betrixaban) was approved by the FDA on June 23, 2017. Learn more.
  • Cerdulatinib – Investigational, oral, dual-spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitior. Portola has worldwide rights to develop and commercialize cerdulatinib. Learn more.
Stock Info
NASDAQPTLA
Corporate Presentation
Recent News
Apr 1, 2020

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on March 31, 2020, the Compensation Committee of the Board of Directors approved, effective as of March 31, 2020, the grant to...

Mar 18, 2020

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced proactive steps the Company is taking in support of public health efforts to prevent furtherspread of coronavirus (or COVID-19) around...

Mar 16, 2020

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only FDA-approved...

More ›

Annual Report